(VIANEWS) – Shares of Novavax (NASDAQ: NVAX) slid by a staggering 23.08% in 10 sessions from $22.14 at 2022-11-10, to $17.03 at 14:10 EST on Thursday, following the last session’s upward trend. NASDAQ is jumping 0.99% to $11,285.32, after two successive sessions in a row of gains.
Novavax’s last close was $17.03, 92.8% below its 52-week high of $236.50.
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Earnings Per Share
As for profitability, Novavax has a trailing twelve months EPS of $-7.27.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -898.2%.
Annual Top and Bottom Value
Novavax stock was valued at $17.03 as of 14:10 EST. This is way below its 52 week high of $236.50, and higher than its 52-week low at $16.00.
Novavax sales growth was 227.8% in the current quarter, and 153.2% the following.
Novavax’s intraday variation average for the week and quarter ended last week was negative at 5.23% and negative at 0.02% respectively. It is positive however, at 5.50%.
Novavax had the highest average volatility amplitude at 5.23% last week, 5.19% last month and 5.50% in its final quarter.
Growth Estimates Quarters
For the current quarter, the company expects to grow by 136.7% and 113.3% respectively.
More news about Novavax (NVAX).